Loading...
Loading...
Browse all stories on DeepNewz
VisitChange in Prescription Rates for Humira Biosimilars at Major Pharmacies by End of 2024
No change • 25%
Increase by up to 20% • 25%
Increase by 21% to 40% • 25%
Increase more than 40% • 25%
Pharmacy utilization reports and industry analytics
CVS Health Replaces Humira with Hyrimoz on April 1, Biosimilar Market Share Surges to 36%
Apr 16, 2024, 02:25 PM
Following a strategic decision by CVS Health, credited by analysts including Elizabeth Anderson from Evercore ISI, there has been a significant increase in the prescription rates of biosimilar versions of Humira, specifically Hyrimoz. CVS Health removed Humira from its major commercial formularies on April 1st and replaced it with Hyrimoz, a biosimilar jointly marketed by its subsidiary Cordavis. This change led to a surge in new prescriptions for Hyrimoz, with the market share of biosimilar versions of Humira jumping from 5% to 36% in just the first week of April.
View original story
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Remains 9 • 25%
10 to 12 • 25%
13 to 15 • 25%
More than 15 • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 20% • 20%
20% to 35% • 20%
36% to 50% • 20%
51% to 65% • 20%
More than 65% • 20%
Increase by over 50% • 25%
Increase by 20-50% • 25%
Increase by less than 20% • 25%
Decrease • 25%
No new approvals • 25%
1 new approval • 25%
2 new approvals • 25%
3 or more new approvals • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% increase • 25%
10% to 20% increase • 25%
20% to 30% increase • 25%
More than 30% increase • 25%
Stock price increases by more than 20% • 25%
Stock price increases by 10-20% • 25%
Stock price increases by less than 10% • 25%
Stock price decreases • 25%
51% to 70% • 25%
More than 70% • 25%
Less than 30% • 25%
30% to 50% • 25%